genOway
Develops custom genetically modified preclinical models for biopharma and academic research.
ALGEN | PA
Overview
Corporate Details
- ISIN(s):
- FR0004053510
- LEI:
- 969500HMHUPR3KYXUT19
- Country:
- France
- Address:
- 31 RUE SAINT JEAN DE DIEU, 69007 LYON
- Website:
- https://www.genoway.com
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Founded in 1999, genOway is a global biotechnology company specializing in the design and development of genetically modified preclinical models. The company provides a comprehensive portfolio of mouse, rat, and cell line models to bio-pharmaceutical companies, life sciences organizations, and academic researchers. genOway offers both a catalog of validated models and customized model creation services tailored to specific scientific questions. Its core mission is to enhance the predictability of preclinical research, helping to bridge the gap between laboratory findings and clinical success for new therapies. The company leverages deep expertise in biological physiology and a collaborative approach to deliver solutions for clients, including many of the world's top pharmaceutical companies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-18 18:30 |
Regulatory Filings
Accélération du développement en Chine : la coentreprise genOway Shanghai devie…
|
French | 176.7 KB | ||
| 2025-03-27 17:55 |
Earnings Release
Résultats annuels 2024 - genOway accélère le déploiement de son plan stratégiqu…
|
French | 223.0 KB | ||
| 2025-01-20 18:00 |
Earnings Release
Croissance solide de +10% de l'activité en 2024 à 22,1 M EUR
|
French | 194.7 KB | ||
| 2024-11-04 18:00 |
Regulatory Filings
Lutte contre l'obésité et les maladies métaboliques : les modèles humanisés de …
|
French | 130.1 KB | ||
| 2024-09-23 18:00 |
Earnings Release
Résultats semestriels 2024 conformes avec les objectifs du nouveau plan stratég…
|
French | 207.7 KB | ||
| 2024-07-18 18:00 |
Earnings Release
Un 1er semestre 2024 en croissance de +15%, de bon augure en pleine mise en oeu…
|
French | 176.4 KB | ||
| 2024-07-04 18:00 |
Business and Financial Review
Bilan semestriel du contrat de liquidité
|
French | 355.0 KB | ||
| 2024-06-25 17:55 |
Regulatory Filings
Solide démarrage du développement de la coentreprise genOway Shanghai en Chine
|
French | 198.0 KB | ||
| 2024-03-28 18:00 |
Regulatory Filings
Organisation d'une visioconférence destinée aux investisseurs individuels
|
French | 128.0 KB | ||
| 2024-03-26 17:45 |
Earnings Release
Résultats annuels 2023 : genOway poursuit sur sa lancée avec une croissance de …
|
French | 219.5 KB | ||
| 2024-02-09 11:00 |
Regulatory Filings
genOway fait son entrée au palmarès 2024 des 500 ' Champions de la croissance '
|
French | 129.5 KB | ||
| 2024-01-22 08:00 |
Regulatory Filings
genOway participe à la 1ère édition du Retail Day organisée par Euroland Corpor…
|
French | 125.7 KB | ||
| 2024-01-16 18:05 |
Board/Management Information
genOway dévoile Route 50+, son nouveau plan stratégique visant à bâtir un leade…
|
French | 198.9 KB | ||
| 2024-01-16 18:00 |
Earnings Release
genOway dépasse le seuil des 20 M EUR de chiffre d'affaires en 2023, porté par …
|
French | 176.3 KB | ||
| 2023-11-22 18:00 |
Report Publication Announcement
Initiation de la couverture du titre genOway par Euroland Corporate
|
French | 100.2 KB |
Automate Your Workflow. Get a real-time feed of all genOway filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for genOway
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for genOway via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-17 | N/A | Other | Sell | 1,700 | 8,160.00 EUR |
| 2023-12-15 | N/A | Other | Sell | 5,000 | 22,000.00 EUR |
| 2023-11-23 | N/A | Other | Sell | 500 | 2,100.00 EUR |
| 2023-10-23 | N/A | Other | Sell | 100 | 390.00 EUR |
| 2023-09-25 | N/A | Other | Buy | 5,000 | 20,000.00 EUR |
| 2023-05-04 | N/A | Other | Buy | 60,000 | 222,000.00 EUR |
| 2023-05-02 | N/A | Other | Sell | 20,000 | 74,000.00 EUR |
Peer Companies
%20Co.%2C%20Ltd/other/SLSBioSpecialty_Lab_Solution_Bio_Co._Ltd-logo.jpg){kind=logo}
